EFS
Figure 2. · Panel A
Panel A 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Satvika Bharadwaj, Germán Corredor, Hilmi Al-Shakhshir, Sebastian Medina, Sahar N Almahfouz, Rohan Dhamdhere, Tilak Pathak, Pingfu Fu, Yuan Liu, Shipra Gandhi, Sunil Badve, Anant Madabhushi
Clin Cancer Res 32(12) 2508-2518
PURPOSE: Trastuzumab-based chemotherapy has improved outcomes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but treatment benefit varies among patients. Predictive signatures are needed to identify patients most likely to respond to these therapies. EXPERIMENTAL DESIGN: We developed Density and Spatial architecture of Tumor-Infiltrating Lymphocytes (DeSTIL), a computational signature derived from hematoxylin and eosin slides. The signature captures spatial organization of immune cells and interactions with nonimmune cells. DeSTIL was trained on HER2+ breast cancer slides from The Cancer Genome Atlas (n = 250) and validated in a phase III National Surgical Adjuvant Breast and Bowel Project (NSABP) B-41 randomized clinical trial (n = 221), which compared chemotherapy plus trastuzumab, lapatinib, or combination. The DeSTIL scores were dichotomized into positive and negative groups, and event-free survival (EFS) was assessed using Cox proportional hazards with interaction terms. RESULTS: In NSABP B-41, DeSTIL-positive patients (n = 61) showed significantly improved event-free survival (EFS) with trastuzumab compared with the combination arm [hazard ratio (HR) = 0.09; 95% confidence interval (CI) = 0.01-0.77; P = 0.006] and a significant signature-treatment interaction (P = 0.024). No EFS difference was observed in DeSTIL-negative patients (n = 160). Gene expression analysis supported the image-derived signature stratifying DeSTIL-positive and DeSTIL-negative tumors. In an exploratory pathologic complete response analysis, a classifier trained on University Hospitals Cleveland slides achieved AUCs of 0.70 in the training cohort and 0.63 in the trastuzumab arm of the NSABP B-41 validation cohort. CONCLUSIONS: DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.
1 个 Figure · 4 个 KM 面板
Treatment outcomes (event) stratified by DeSTIL in the NSABP B-41 clinical trial, with EFS shown on the x -axis. Row 1: Kaplan–Meier curves for ( A ) DeSTIL-positive and ( B ) DeSTIL-negative patient groups comparing trastuzumab and the combination therapy, respectively. Row 2: Kaplan–Meier curves for ( C ) DeSTIL-positive and ( D ) DeSTIL-negative patient groups comparing trastuzumab- and lapatinib-containing regimens (lapatinib alone or combination therapy). The x -axis represents EFS, whereas the y -axis represents survival probability, and patients without events were censored at last follow-up.
Figure 2. · Panel A
Panel A 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. · Panel B
Panel B 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. · Panel C
Panel C 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2. · Panel D
Panel D 是同一 Figure 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。